The earnings call highlighted Esperion's robust financial performance with significant revenue growth and strategic achievements, such as achieving operating income for the first time and strong international partnerships. While there were some concerns about collaboration revenue and milestone payments, the positive aspects of the company's growth and strategic initiatives significantly outweigh the challenges.

Company Guidance -

Q3 2025

During Esperion's Second Quarter 2025 earnings call, the company reported strong financial performance, highlighted by a 42% year-over-year increase in U.S. net product revenue, reaching $40.3 million, and a total revenue growth of 12% year-over-year to $82.4 million. This period marked their first quarter of operating income from ongoing business, approximately $15 million, and a sequential quarterly revenue growth of 15%. Esperion emphasized the robust adoption of their products NEXLETOL and NEXLIZET, driven by effective marketing strategies and favorable reimbursement landscapes, which led to over 80% approval rates among targeted prescribers. The company also noted significant gains in digital engagement, with 38% of prescriptions prompted by digital-only interactions. Their international partnerships contributed to the revenue, with a 30% increase in royalty revenue from Daiichi Sankyo Europe. Looking ahead, Esperion is optimistic about transitioning to sustainable profitability by the first quarter of 2026 and anticipates continued growth fueled by both domestic and international market expansions.

Record Revenue Growth

Esperion reported a 12% year-over-year increase in total revenue for Q2 2025, reaching $82.4 million. U.S. net product sales saw a 42% increase year-over-year to $40.3 million.

First Operating Income

Esperion achieved its first quarter of operating income from ongoing business, amounting to approximately $15 million, signaling a transition towards sustainable profitability by Q1 2026.

Significant Increase in Prescriptions

Esperion reported double-digit sequential growth in prescriptions, with a 10% increase in total retail prescription equivalents from Q1 2025.

Strong International Performance

Royalty revenue from Daiichi Sankyo Europe increased 30% from Q1 2025, and the company surpassed the 500,000 patient mark in Europe.

Successful Marketing Campaigns

The 'Can't take a statin? Make NEXLIZET happen' campaign drove significant brand awareness, with 650,000 visits to the consumer website and 600,000 click-throughs to the physician site.

Intellectual Property Settlements

Esperion reached settlement agreements with three generic manufacturers to delay the marketing of generic NEXLETOL in the U.S. until 2040.

Esperion (ESPR) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ESPR Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	0.02 / -	-0.15	―	―	―
Aug 11, 2025	2025 (Q2)	-0.15 / -0.02	-0.33	93.94% (+0.31)
May 06, 2025	2025 (Q1)	-0.15 / -0.21	0.34	-161.76% (-0.55)
Mar 04, 2025	2024 (Q4)	-0.15 / -0.11	-0.5	78.00% (+0.39)
Nov 07, 2024	2024 (Q3)	-0.17 / -0.15	-0.37	59.46% (+0.22)
Aug 12, 2024	2024 (Q2)	-0.17 / -0.33	-0.46	28.26% (+0.13)
May 07, 2024	2024 (Q1)	0.05 / 0.34	-0.79	143.04% (+1.13)
Feb 27, 2024	2023 (Q4)	-0.48 / -0.50	-0.76	34.21% (+0.26)
Nov 07, 2023	2023 (Q3)	-0.43 / -0.37	-0.81	54.32% (+0.44)
Aug 01, 2023	2023 (Q2)	-0.61 / -0.46	-1.05	56.19% (+0.59)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ESPR Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 11, 2025	$1.87	$1.84	-1.60%
May 06, 2025	$1.05	$0.98	-6.67%
Mar 04, 2025	$1.58	$1.77	+12.03%
Nov 07, 2024	$2.21	$2.11	-4.52%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Esperion (ESPR) report earnings?

Esperion (ESPR) is schdueled to report earning on Nov 05, 2025, TBA (Confirmed).

What is Esperion (ESPR) earnings time?

Esperion (ESPR) earnings time is at Nov 05, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ESPR EPS forecast?

ESPR EPS forecast for the fiscal quarter 2025 (Q3) is 0.02.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing